Welcome to our dedicated page for Atrium Therapeutics news (Ticker: RNA), a resource for investors and traders seeking the latest updates and insights on Atrium Therapeutics stock.
Avidity Biosciences, Inc. (Nasdaq: RNA) generates news flow centered on its development of Antibody Oligonucleotide Conjugates (AOCs™), a class of RNA therapeutics designed to combine monoclonal antibody specificity with oligonucleotide precision. Company announcements frequently highlight progress across its late-stage neuromuscular pipeline, including programs for myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD).
News items for RNA often cover clinical trial milestones, such as topline and long-term data from the EXPLORE44® and EXPLORE44-OLE™ studies of delpacibart zotadirsen (del-zota) in DMD44, enrollment and data plans for the HARBOR™ Phase 3 trial of del-desiran in DM1, and development updates for del-brax and the FORTITUDE™ and FORTITUDE-3™ programs in FSHD. Regulatory developments are another key theme, including the FDA’s Breakthrough Therapy designation for del-zota and disclosures about planned Biologics License Application (BLA) submissions.
Investors following Avidity’s news can also expect coverage of financing activities, such as public offerings of common stock, collaboration milestones with partners like Eli Lilly and Company and Bristol Myers Squibb, and updates on the company’s cash position as reported in periodic financial results. Corporate and strategic news includes participation in scientific and investor conferences, as well as detailed announcements about the definitive merger agreement with Novartis AG and the planned separation of early-stage precision cardiology programs into a new company referred to as SpinCo.
In addition, Avidity regularly reports on its engagement with patient and advocacy communities, particularly during National Muscular Dystrophy Awareness Month and events focused on Duchenne muscular dystrophy, myotonic dystrophy, FSHD and rare diseases. For readers tracking RNA, this news page provides a centralized view of clinical, regulatory, financial and transaction-related developments that shape the company’s trajectory.
Avidity Biosciences (Nasdaq: RNA) announced positive results for delpacibart zotadirsen (AOC 1044) in the Phase 1/2 EXPLORE44™ trial for Duchenne muscular dystrophy (DMD44). The drug demonstrated:
- Unsurpassed muscle concentrations of PMO at 200 nM after three 5 mg/kg doses
- 37% increase in exon 44 skipping, up to 66% with 5 mg/kg dose
- 25% increase in dystrophin production, restoring up to 54% of normal levels
- Over 80% reduction in creatine kinase levels
- Favorable safety and tolerability profile
These results suggest potential for changing the treatment paradigm for DMD44 patients. The company plans to expedite the regulatory path for delpacibart zotadirsen and advance additional exon-skipping DMD candidates.
Avidity Biosciences (Nasdaq: RNA) has announced inducement grants for its new Chief Legal Officer and Corporate Secretary, John B. Moriarty, Jr. The grants, approved on August 1, 2024, include:
- A non-qualified stock option to purchase 160,000 shares of common stock
- 25,000 restricted stock units (RSUs)
These awards were granted under the company's 2022 Employment Inducement Incentive Award Plan, in compliance with Nasdaq Listing Rule 5635(c)(4). The stock option has an exercise price of $44.57 per share, equal to the closing price of Avidity's stock on August 1, 2024. The stock option will vest over four years, while the RSUs will vest in four equal annual installments, both subject to Mr. Moriarty's continued employment.
Avidity Biosciences (Nasdaq: RNA) has appointed John B. Moriarty, Jr., J.D. as Chief Legal Officer and Corporate Secretary, effective immediately. With nearly 30 years of industry experience, Moriarty brings extensive legal expertise to guide the company through transformational growth. He succeeds John W. Wallen III, Ph.D., J.D., who will remain with the company through year-end and transition as a consultant.
Moriarty's previous roles include Executive VP and Chief Legal Officer at Mirati Therapeutics, Chief Legal Officer at Olema Oncology, and General Counsel positions at Portola Pharmaceuticals, Alexion, and Elan His appointment comes as Avidity advances three clinical development programs for rare muscle diseases and expands its AOC platform pipeline.
Avidity Biosciences (Nasdaq: RNA) has announced inducement grants under Nasdaq Listing Rule 5635(c)(4). The company's Human Capital Management Committee granted non-qualified stock options to purchase 128,200 shares of common stock and 22,100 restricted stock units (RSUs) to six new non-executive employees. These awards were granted under the 2022 Employment Inducement Incentive Award Plan as inducements for new employees joining Avidity.
The stock options have an exercise price of $45.12 per share, equal to the closing price of Avidity's common stock on July 19, 2024. The options will vest over four years, with 25% vesting after one year and the remainder vesting monthly over 36 months. The RSUs will vest in four equal annual installments. Both are subject to continued employment with Avidity.
Avidity Biosciences (Nasdaq: RNA) announced the granting of non-qualified stock options and restricted stock units (RSUs) on June 20, 2024. The Human Capital Management Committee awarded options to purchase 173,300 shares and 86,650 RSUs to 14 new non-executive employees under the 2022 Employment Inducement Incentive Award Plan. The exercise price for the options is $37.61 per share, matching the closing price on June 20, 2024. The options and RSUs will vest over four years, contingent on continued employment. These inducements comply with Nasdaq Listing Rule 5635(c)(4).
Avidity Biosciences (Nasdaq: RNA) has partnered with the FSHD Society to raise awareness of facioscapulohumeral muscular dystrophy (FSHD) on World FSHD Day. In a webinar today at 1:00 p.m. ET, they will present promising initial data from their Phase 1/2 FORTITUDE trial. The trial investigates del-brax, the first therapy targeting the root cause of FSHD, showing over 50% reduction in DUX4 regulated genes and functional improvements for participants. Avidity emphasizes their commitment to advancing treatments for FSHD, a debilitating genetic disorder. The FSHD Society, a leading patient organization, supports this initiative, hopeful for a potential treatment from the FORTITUDE study.
Avidity Biosciences has concluded an upsized public offering of 12,132,500 shares of common stock, priced at $38.00 per share, including 1,582,500 shares sold under the underwriters' option. The gross proceeds from the offering amount to $461 million before deductions. The funds will support the development of Avidity's clinical programs, research and development of its AOC platform, and general corporate purposes. Joint bookrunning managers for the offering included TD Cowen, Leerink Partners, Cantor, Barclays, and Wells Fargo Securities. The offering was made under an automatically effective shelf registration filed with the SEC.
Avidity Biosciences (Nasdaq: RNA), a biopharmaceutical company focused on developing RNA therapeutics known as Antibody Oligonucleotide Conjugates (AOCs™), announced its participation in the TD Cowen Genetic Medicines & RNA Summit on June 20, 2024. The presentation will occur at 8:20 a.m. PT/11:20 a.m. ET. A live webcast and replay of the event will be accessible on Avidity’s investor relations webpage.
Avidity Biosciences (Nasdaq: RNA) announced the pricing of a public offering of 10,550,000 shares of its common stock at $38.00 per share, expected to raise $400.9 million in gross proceeds. The offering is set to close around June 17, 2024, pending customary conditions. Avidity has also provided underwriters a 30-day option to purchase up to an additional 1,582,500 shares. Proceeds will support the development of clinical programs, research on its AOC platform, and general corporate purposes. TD Cowen, Leerink Partners, Cantor, Barclays, and Wells Fargo are the joint bookrunning managers.
Avidity Biosciences announced a proposed public offering to sell $300 million of common stock, with an additional $45 million available via a 30-day underwriters' option. The proceeds will fund clinical program development, AOC platform R&D, working capital, and general corporate purposes. Completion of the offering is subject to market conditions, and the terms are uncertain. Joint bookrunning managers include TD Cowen, Leerink Partners, Cantor, Barclays, and Wells Fargo Securities. The offering is pursuant to an automatically effective shelf registration statement filed with the SEC.